Reduce risk. Accelerate development.
Trust Velcoity to deliver integrated, high-performance sites at scale.
220+ Investigators: World-class expertise, experienced sites
80+ sites, 4 countries: Diverse patient populations, specialty partners
Operational excellence: Unparalleled recruitment, quality, and care
Accelerated Site Selection
Before trials begin, Velocity will expedite your site selection process by providing fast, accurate feasibility responses and a ‘one contact, one contract’ approach for all sites.
~48 hours compared to industry average of 2+ weeks. 50% faster IRB review cycles compared to peers; includes submission, clarification, and approval timelines.
Predictable Recruitment
With Velocity, an industry-leading central recruitment team, a database of ~1,500,000 patients, and proprietary, AI-driven VISION technology are supporting your trial.
Compared to other sites supporting a 2024 global Phase 3 trial with 25+ Velocity sites across two countries, 130+ sites total.
Strategic Alignment
By providing strategic alignment with sites at scale — including options for performance-based contracting and joint KPI governance — you can get to startup and FPI faster.
Compared to other sites supporting a 2024 U.S. trial with 20+ Velocity sites, 130+ sites total.
Proof in Performance
See how Velocity is delivering at scale for trials worldwide.
Case Study #3
Enrolling 1,400+ Participants Across 3 Countries for a Phase 3 Flu Vaccine Trial
The Trial
Client: CSL Seqirus
Title: A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) (V201-03)
Target population: Ages ≥50, healthy or with stable comorbidities
The Objective
CSL Seqirus partnered with Velocity to deliver patients in the U.S., U.K., and Germany for a Phase 3 flu vaccine trial. Worldwide, 25 Velocity sites were selected to deliver a significant portion of the trial’s 7,700 participants.
Trial population subsets included adults aged >65 and participants with stable comorbidities that increased the risk of complications from influenza infection.
Global enrollment goal: 7,700 participants
Initial Velocity enrollment goal: 1,070 patients (13.9% of trial) across 25 sites
Target population: Adults aged ≥50, stratified into three age groups
Enrollment window: 1 month
The Result
Working as a unified site organization across three countries, Velocity successfully met and exceeded enrollment targets and timelines.
Velocity delivered 1,474 participants (137.8% of goal, 19.1% of trial) across three countries.
Due to the speed of enrollment by Velocity’s sites, CSL Seqirus invited seven Velocity sites to fill a second cohort of 40 participants ages >65 at each of seven sites in the U.S. Velocity accepted and filled the cohort in one week.
In Germany, all Velocity sites exceeded enrollment targets and were offered to double initial enrollment targets. This performance and versatility demonstrate Velocity’s effectiveness as a global site partner.
Filled allotted U.S. cohort in 2 weeks
Filled a second, invite-only cohort of ages >65 in 1 week
Over-enrolled in Germany in 1 month
Achieved a low 4.2% screen fail rate
Case Study #4
Enrolling 600+ Participants for a Fully Decentralized Asthma Trial (BATURA)
The Trial
Client: Avillion and AstraZeneca
Title: A Multicenter, Randomized, Double-blind, Parallel group, Event-driven, Decentralized, Phase III Study comparing PT027 (Budesonide/Albuterol) with PT007 (Albuterol) Administered as needed in Adolescents and Adults with Asthma (BATURA)
Target population: Ages ≥12, with asthma, and treated with short-acting beta-agonists (SABA) alone, low-dose inhaled corticosteroids (ICS) plus SABA, or leukotriene modifiers plus SABA
The Objective
Avillion and AstraZeneca partnered with Velocity to test a novel asthma treatment for teens and adults as part of the fully decentralized BATURA trial. Targeting people aged 12 and older with asthma, Velocity was selected to support the trial in the U.S.
Global enrollment goal: 2,500 participants
Velocity goal: Velocity goal: 569 participants across 14 sites (U.S.)
Enrollment window: 12 month
The Result
As one of seven networks (56 sites) involved, Velocity delivered 24% of trial participants. Emerging as the highest enrolling network of brick-and-mortar sites, Velocity exceeded its enrollment goal and demonstrated its ability to efficiently support a decentralized trial.
Velocity delivered 604 participants (24% of trial, 106% of target) with ~43 enrolled per site.
In October 2024, after an independent data monitoring committee recommended the trial stop early due to overwhelming efficacy at pre-planned analysis, Avillion and AstraZeneca announced positive results from the BATURA trial.
"Given our positive experience with Velocity, Avillion intends to establish a close working relationship and engage early on projects that could benefit from Velocity’s high-quality patient enrollment capability."
Robert Rees, PhD
Senior Director, Clinical Programs, Avillion
Delivering at Scale
Led by experts with extensive Sponsor/CRO experience, Velocity is built to deliver high quality, predictability, and unprecedented efficiency, even for the most complex clinical trials.
Providing Greater Certainty for Clinical Trials
Let's talk about your next trial